|
Jiang Zhong Pharmaceutical Co., Ltd (600750.SS) Évaluation DCF
CN | Healthcare | Drug Manufacturers - Specialty & Generic | SHH
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Jiang Zhong Pharmaceutical Co.,Ltd (600750.SS) Bundle
Gardez un aperçu de votre analyse d'évaluation de votre Jiang Zhong Pharmaceutical Co., Ltd (600750SS) avec notre calculatrice DCF de pointe! Ce modèle Excel est préchargé avec des données réelles (600750SS), vous permettant d'ajuster les prévisions et les hypothèses pour déterminer avec précision la valeur intrinsèque de Jiang Zhong Pharmaceutical.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,449.4 | 2,441.5 | 2,874.0 | 3,811.6 | 4,390.1 | 4,161.0 | 3,943.8 | 3,738.0 | 3,542.9 | 3,358.0 |
| Revenue Growth, % | 0 | -0.32468 | 17.72 | 32.63 | 15.18 | -5.22 | -5.22 | -5.22 | -5.22 | -5.22 |
| EBITDA | 635.1 | 703.3 | 745.8 | 881.6 | 1,030.2 | 1,059.2 | 1,003.9 | 951.5 | 901.9 | 854.8 |
| EBITDA, % | 25.93 | 28.81 | 25.95 | 23.13 | 23.47 | 25.46 | 25.46 | 25.46 | 25.46 | 25.46 |
| Depreciation | 113.2 | 113.0 | 115.7 | 122.5 | 122.3 | 160.4 | 152.1 | 144.1 | 136.6 | 129.5 |
| Depreciation, % | 4.62 | 4.63 | 4.03 | 3.21 | 2.79 | 3.86 | 3.86 | 3.86 | 3.86 | 3.86 |
| EBIT | 521.9 | 590.2 | 630.0 | 759.1 | 907.9 | 898.8 | 851.9 | 807.4 | 765.3 | 725.3 |
| EBIT, % | 21.31 | 24.18 | 21.92 | 19.92 | 20.68 | 21.6 | 21.6 | 21.6 | 21.6 | 21.6 |
| Total Cash | 1,581.4 | 2,080.9 | 2,773.8 | 2,744.2 | 1,382.9 | 2,911.0 | 2,759.1 | 2,615.1 | 2,478.6 | 2,349.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1,143.1 | 896.5 | 793.5 | 775.5 | 544.9 | 1,196.3 | 1,133.9 | 1,074.7 | 1,018.6 | 965.5 |
| Account Receivables, % | 46.67 | 36.72 | 27.61 | 20.34 | 12.41 | 28.75 | 28.75 | 28.75 | 28.75 | 28.75 |
| Inventories | 242.5 | 246.7 | 378.0 | 382.2 | 406.2 | 436.4 | 413.6 | 392.0 | 371.6 | 352.2 |
| Inventories, % | 9.9 | 10.11 | 13.15 | 10.03 | 9.25 | 10.49 | 10.49 | 10.49 | 10.49 | 10.49 |
| Accounts Payable | 56.3 | 45.6 | 205.7 | 236.8 | 118.4 | 168.4 | 159.6 | 151.3 | 143.4 | 135.9 |
| Accounts Payable, % | 2.3 | 1.87 | 7.16 | 6.21 | 2.7 | 4.05 | 4.05 | 4.05 | 4.05 | 4.05 |
| Capital Expenditure | -76.3 | -182.5 | -188.5 | -345.6 | -208.9 | -257.8 | -244.3 | -231.6 | -219.5 | -208.0 |
| Capital Expenditure, % | -3.12 | -7.48 | -6.56 | -9.07 | -4.76 | -6.2 | -6.2 | -6.2 | -6.2 | -6.2 |
| Tax Rate, % | 21.05 | 21.05 | 21.05 | 21.05 | 21.05 | 21.05 | 21.05 | 21.05 | 21.05 | 21.05 |
| EBITAT | 427.5 | 482.6 | 511.3 | 604.7 | 716.8 | 725.2 | 687.3 | 651.5 | 617.5 | 585.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -864.9 | 644.7 | 570.4 | 426.5 | 718.4 | -3.8 | 671.5 | 636.5 | 603.2 | 571.8 |
| WACC, % | 7.6 | 7.6 | 7.6 | 7.59 | 7.59 | 7.6 | 7.6 | 7.6 | 7.6 | 7.6 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 1,934.1 | |||||||||
| Long Term Growth Rate, % | 3.00 | |||||||||
| Free cash flow (T + 1) | 589 | |||||||||
| Terminal Value | 12,815 | |||||||||
| Present Terminal Value | 8,887 | |||||||||
| Enterprise Value | 10,821 | |||||||||
| Net Debt | -1,332 | |||||||||
| Equity Value | 12,153 | |||||||||
| Diluted Shares Outstanding, MM | 632 | |||||||||
| Equity Value Per Share | 19.22 |
Benefits You Will Receive
- Authentic 600750 Financial Data: Pre-loaded with Jiang Zhong Pharmaceutical’s historical and future projections for detailed analysis.
- Completely Customizable Template: Easily adjust key variables such as revenue growth, WACC, and EBITDA percentage.
- Real-Time Calculations: Instantly view updates to Jiang Zhong's intrinsic value based on your modifications.
- Professional Valuation Tool: Tailored for investors, analysts, and consultants in search of precise DCF evaluations.
- User-Friendly Interface: Intuitive layout and straightforward guidance suitable for all skill levels.
Key Features
- 🔍 Real-Life JZPH Financials: Pre-filled historical and projected data for Jiang Zhong Pharmaceutical Co., Ltd (600750SS).
- ✏️ Fully Customizable Inputs: Modify all key parameters (yellow cells) such as WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Integrated formulas determine Jiang Zhong's intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: View Jiang Zhong's valuation immediately after making adjustments.
- Scenario Analysis: Evaluate and compare results for different financial assumptions side-by-side.
How It Functions
- Step 1: Download the prebuilt Excel template featuring Jiang Zhong Pharmaceutical Co., Ltd's data.
- Step 2: Navigate through the pre-filled sheets to grasp the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly observe recalibrated results, including the intrinsic value of Jiang Zhong Pharmaceutical Co., Ltd (600750SS).
- Step 5: Make well-informed investment choices or create reports based on the generated outputs.
Why Choose Our Financial Calculator for Jiang Zhong Pharmaceutical Co., Ltd (600750SS)?
- Accuracy: Utilizes real financial data from Jiang Zhong Pharmaceutical to guarantee precise results.
- Flexibility: Allows users to freely experiment with and adjust input values.
- Time-Saving: Eliminate the need to create a DCF model from the ground up.
- Professional-Grade: Crafted with the expertise and attention to detail expected by industry leaders.
- User-Friendly: Designed for ease of use, suitable even for those with limited financial modeling skills.
Who Can Benefit from This Product?
- Individual Investors: Make educated choices regarding the purchase or sale of shares in Jiang Zhong Pharmaceutical Co.,Ltd (600750SS).
- Financial Analysts: Enhance valuation workflows with comprehensive financial models tailored for Jiang Zhong Pharmaceutical Co.,Ltd.
- Consultants: Provide timely and precise valuation insights for clients focused on Jiang Zhong Pharmaceutical Co.,Ltd.
- Business Owners: Gain insights into how industry leaders like Jiang Zhong Pharmaceutical Co.,Ltd are valued to inform your own business strategy.
- Finance Students: Explore valuation methods using practical data and real-life scenarios related to Jiang Zhong Pharmaceutical Co.,Ltd.
Overview of the Template's Features
- Preloaded Jiang Zhong Pharmaceutical Data: Historical and forecasted financial metrics, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Advanced worksheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Cells highlighted in yellow for customizing revenue growth, tax rates, and discount rates.
- Financial Statements: Detailed annual and quarterly financial statements for thorough analysis.
- Key Ratios: Ratios for profitability, leverage, and efficiency to assess performance.
- Dashboard and Charts: Visual representations of valuation results and underlying assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.